MET and glioblastoma: Measuring HGF/Met pathway activity in GBM patients is a logical basis for selecting those most likely to benefit from HGF/Met-targeted therapeutics; the results presented here further suggest that monitoring Met pathway activity and HGF production in those patients could provide early indications of acquired resistance, that Met kinase inhibitors may still be efficacious when resistance occurs and that targeting the other critical mediators of resistance identified here may provide effective alternative or combinatorial treatments.